TG Therapeutics Inc (TGTX) Q3 2025 Earnings Call Highlights: Record Revenue Surge and Strategic ...

TG Therapeutics Inc (TGTX) reports a 93% revenue increase, driven by BRIUMVI sales, while navigating competitive challenges ...

TG Therapeutics raises BRIUMVI 2025 revenue guidance to $585M while advancing subcutaneous pipeline

Q3 2025 Management View CEO Michael Weiss reported, "Our flagship product, BRIUMVI for relapsing MS continues to outperform, ...

TG Therapeutics Reports Third Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance

Third quarter 2025 total revenue of $161.7 million, including BRIUMVI U.S. net revenue of $152.9 millionRaises full year 2025 global revenue ...
Investor's Business Daily on MSN

Highly Watched TG Therapeutics Smashes Profit Views — But There's A Caveat

TG Therapeutics stock toppled early Monday on a key caveat that undercut the company's massive third-quarter profit beat.

TG Therapeutics Q3 Earnings: Strong Quarter For Briumvi As CD20 Market Grows

TG Therapeutics, Inc. posted a strong Q3 with soaring Briumvi sales and increased guidance. Click for my updated look at TGTX stock post earnings.

Earnings Preview For TG Therapeutics

TG Therapeutics (NASDAQ: TGTX) will release its quarterly earnings report on Monday, 2025-11-03. Here's a brief overview for investors ahead of the announcement. Analysts anticipate TG Therapeutics to ...

TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update

In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Earnings Call. A live webcast of this ...